WEBULL
WebtradeDownload

Axsome Therapeutics (AXSM) Unveils New Depression And Alzheimer’s Agitation Data At Psych Congress 2026

Simply Wall St · 1d ago
  • Axsome Therapeutics (NasdaqGM: AXSM) presented new clinical data in major depressive disorder and Alzheimer’s disease agitation at Psych Congress 2026.
  • The company also shared additional scientific findings from across its psychiatry and neurology pipeline at the same meeting.
  • Management highlighted how the new evidence base could inform future clinical practice and potential regulatory discussions for its programs.
  • The fresh data in major depressive disorder and Alzheimer’s disease agitation is worth weighing alongside the rest of our Axsome findings. Take a look at 3 other big wins we have identified for Axsome Therapeutics.

This focus on psychiatry and neurology is not unique to Axsome Therapeutics, so it is worth scanning other under-the-radar players exposed to similar themes through our screener containing 16 high quality undiscovered gems.

NasdaqGM:AXSM Earnings & Revenue Growth as at Sep 2026
NasdaqGM:AXSM Earnings & Revenue Growth as at Sep 2026

Axsome Therapeutics focuses on central nervous system disorders in the US. Fresh psychiatry and neurology findings feed directly into its effort to develop new treatments for conditions like major depressive disorder and Alzheimer’s disease agitation within the broader pharmaceuticals space.

Does the team leading Axsome Therapeutics have what it takes? See our full breakdown of the management team's track record and compensation.

Fresh CNS data tests Axsome Therapeutics’ diversification story

The investment story for Axsome Therapeutics hinges on whether a broader central nervous system portfolio can support multiple indications across psychiatry and neurology, rather than leaning on a single prescription product. The Psych Congress 2026 posters go straight at that question by adding detail in major depressive disorder and Alzheimer’s agitation.

"The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders..."

See how the full story points towards a $283 fair value for Axsome Therapeutics.

On the bullish side, this batch of data helps show that Axsome Therapeutics is actually filling out the multi indication CNS grid its Narrative describes, not just talking about it. More readouts across depression and Alzheimer’s agitation support the idea that Auvelity and related assets can be used in several high-need settings, which is central to the diversification pitch versus rivals like Biogen or Eli Lilly.

The bear case still has teeth. More indications also mean heavier trial spend, complex payer discussions and a need for strong commercial execution in Alzheimer’s care, where entrenched antipsychotic use and big pharma competition can slow uptake. Analysts have flagged that high expenses and reimbursement pressure could weigh on margins if this richer evidence base does not translate into consistent prescriptions.

News like this only really comes into focus once you have a clear view of Axsome Therapeutics’ longer term story, which is exactly what a Narrative is trying to spell out.

Add Axsome Therapeutics to your Watchlist and get alerts as these catalysts play out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.